Searchable abstracts of presentations at key conferences in endocrinology

ea0084ps1-01-08 | COVID & Thyroid Disease | ETA2022

Graves’ orbitopathy and subacute thyroiditis related to SARS-CoV-2 infection or vaccination: the experience of a single centre in milan, italy

Muller Ilaria , Crivicich Erica , Di Marco Francesco , Curro Nicola , Arosio Maura , Salvi Mario

Background: The Covid-19 pandemic caused by the severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) determined millions of deaths worldwide, thus at the end of 2020 a massive vaccination campaign has been launched. SARS-CoV-2 infection and vaccines have been associated with several thyroid disorders, especially subacute thyroiditis (SAT), Graves’ disease (GD) and orbitopathy (GO). We studied the occurrence of SAT and GO following SARS-CoV-2 infection or vaccinati...

ea0084ps3-12-112 | Graves’ Disease 2 and Orbitopathy | ETA2022

Alemtuzumab-induced graves’ orbitopathy successfully treated with a single dose of rituximab

Di Marco Francesco , Porcaro Laura , Crivicich Erica , Curro Nicola , Arosio Maura , Muller Ilaria , Salvi Mario

Introduction: The humanized antibody anti-CD52+ alemtuzumab has been approved since 2014 for the treatment of relapsing-remitting multiple sclerosis (RRMS). Immune reconstitution after alemtuzumab induces thyroid autoimmunity in 34-41% of patients with RRMS, with Graves’ disease (GD) accounting for 63-65% of cases. Graves’ Orbitopathy (GO) may also occur in 13% of patients after alemtuzumab and is scarcely reported. Here we present the first case of alemtuzumab-induc...

ea0090rc2.1 | Rapid Communications 2: Thyroid | ECE2023

Increased risk of Graves’ orbitopathy following Covid-19 vaccination

Muller Ilaria , Consonni Dario , Crivicich Erica , Di Marco Francesco , Curro Nicola , Salvi Mario

Background: Vaccination is a widely adopted measure against the severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) causing Covid-19 pandemic. Both SARS-CoV-2 infection and Covid-19 vaccines have been associated with several thyroid disorders. We studied the risk of Graves’ orbitopathy (GO) following Covid-19 vaccination.Methods: The study included 98 consecutive patients (71 females and 27 males, mean-age 50 years) attending our tertiary r...

ea0022p816 | Thyroid | ECE2010

A single small dose of rituximab may be effective in Graves' orbitopathy

Covelli Danila , Vannucchi Guia , Curro Nicola , Dazzi Davide , Beck-Peccoz Paolo , Salvi Mario

The anti-CD 20 antibody rituximab (RTX) has been employed in the treatment of several autoimmune diseases and its effect may not involve autoantibody secretion. Preliminary studies have shown that RTX induced improvement of active Graves’ orbitopathy (GO) but caused no change of serum anti-thyroid antibodies in relation to peripheral CD 20+ cells depletion, usually observed at the second week after therapy. A 50-year-old woman with GO predominantly active in the left eye ...

ea0020p120 | Thyroid | ECE2009

Seasonal occurrence of Graves’ disease and associated orbitopathy at diagnosis

Campi Irene , Vannucchi Guia , Covelli Danila , Curro Nicola , Dazzi Davide , Beck-Peccoz Paolo , Salvi Mario

A seasonal occurrence of Graves’ disease (GD) has been reported in previous studies, with a peak of frequency in the warmer half of the year (Ford 1988, 1991, Westphal 1994) or the period of the year with a higher iodine intake (Phillips 1985); other studies (Facciani 2000) have failed to find a different seasonal occurrence of Graves’ orbitopathy (GO). Aim of the present study was to evaluate a possible seasonal difference in the onset of GD and GO in a series of ou...

ea0063gp81 | Thyroid Autoimmune Disorders | ECE2019

Retrospective analysis of the efficacy of three different dose regimens of rituximab in patients with active moderate-severe graves’ orbitopathy

Lazzaroni Elisa , Covelli Danila , Campi Irene , Vannucchi Guia , Curro Nicola , Pirola Giacinta , Guastella Claudio , Dolci Alessia , Arosio Maura , Salvi Mario

Aim: The aim of this retrospective study was to assess the efficacy of different doses of rituximab (RTX) in patients with active moderate-severe Graves’ Orbitopathy (GO).Methods: Overall 40 patients, 5 M/35 F; mean age (± S.D.) 58±11 years were treated with RTX; 21 were smokers. The patients received the following treatment: 14 patients (group 1) a single 100 mg dose; 15 patients (group 2) a single 500 mg dose and 11 Patien...

ea0037gp.27.05 | Thyroid – hyperthyroidism and treatment | ECE2015

Effect of a very low dose of rituximab on active moderate–severe Graves' orbitopathy: an interim report

Vannucchi Guia , Campi Irene , Covelli Danila , Curro Nicola , Dazzi Davide , Avignone Sabrina , Sina Clara , Guastella Claudio , Pignataro Lorenzo , Salvi Mario

Previous studies have shown that Rituximab (RTX) is effective as a disease modifying drug at doses of 500 mg or 1000×2 mg in active Graves’ orbitopathy (GO). We have conducted a pilot study (EUDRACT 2012-001980-53) in which patients with active moderate-severe GO were treated with a single infusion of low dose RTX (100 mg). Ten patients were enrolled of whom seven completed the study at 52 weeks. Five patients did not respond to a previous treatment with i.v. methylp...

ea0016p810 | Thyroid | ECE2008

Effects of rituximab (RTX) treatment on IL-6 and soluble IL-6 receptor secretion in patients with thyroid-associated ophthalmopathy (TAO)

Campi Irene , Vannucchi Guia , Dazzi Davide , Covelli Danila , Bonara Paola , Curro Nicola , Beck-Peccoz Paolo , Salvi Mario

We described a significant clinical response to RTX treatment in patients with active TAO. In order to understand the possible mechanisms of action of RTX, we measured serum concentrations of IL-6 and its soluble receptor (sIL-6R). We treated 10 patients with RTX: 8 women, 2 men aged 31–51 yr with Graves’ disease. We also treated 14 patients with i.v. steroids (IVGC). All had active TAO. In all patients we studied thyroid function, serum autoantibodies and peripheral...

ea0084op-11-54 | Oral Session 11: Young Investigators / Basic | ETA2022

Study of target tissue-resident immune cells in graves’ disease and orbitopathy (star-GO): preliminary findings with a novel extensive immunophenotyping panel

Maioli Sara , Salvi Mario , Moschetti Giorgia , Crosti Mariacristina , Crivicich Erica , Di Marco Francesco , Curro Nicola , Dolci Alessia , Arosio Maura , Mantovani Giovanna , Dayan Colin , Geginat Jens , Muller Ilaria

Background and Aims: Graves’ disease (GD) and orbitopathy (GO) are characterised by the presence of pathological anti-thyrotropin receptor antibodies. In thyroid autoimmunity, especially GD and GO, a dysregulation of several T cell subpopulations has been proposed, especially T regulatory (Treg) and T helper 17 (Th17) cells, determining (auto)immunity inhibition and enhancement, respectively. T follicular cells (Tf) within germinal centres (GC: aggregates of lymphocytes w...

ea0020p68 | Thyroid | ECE2009

Treatment of patients with Graves’ orbitopathy (GO) with rituximab: effects on humoral immunity

Vannucchi Guia , Campi Irene , Bonomi Marco , Curro Nicola , Dazzi Davide , Covelli Danila , Bonara Paola , Persani Luca , Wall Jack , Beck-Peccoz Paolo , Salvi Mario

Rituximab (RTX) is a monoclonal antibody which binds CD20 antigen and induces B cell depletion. It is not known if its therapeutic effect in autoimmune diseases is mediated by modifications of the humoral immune response, namely the antibody production. Aim of the present study was to evaluate the effect of RTX on serum TSH-receptor antibodies, both binding (TBII) and stimulating (TSAb) and on serum antibodies against three orbital antigens, calsequestrin, XIII collagen and th...